International Conference on Defects in Semiconductors

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
European Organisation for Research and Treatment of Cancer, Treatment, Research and development, RNA, AACR, International Conference on Defects in Semiconductors, Baylor College of Medicine, EORTC, National Cancer Institute, Non-small-cell lung cancer, American Association for Cancer Research, Therapy, NCI, Gene, Prostate cancer, Prostate, Small RNA, Baylor University, Promontory, Conference, ICD, Pharmaceutical industry, Platinum, Vaccine, Doctor of Philosophy, Cancer, Research

NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.

Key Points: 
  • The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
  • Researchers also conducted nascent RNA sequencing in human cancer cells (non-small cell lung, prostate and renal cell carcinoma) following one and six hours of PT-112 treatment.
  • "While further validation of these findings is ongoing, this work deepens our understanding of PT-112's specific molecular effects.
  • PT-112 rapidly causes ribosomal biogenesis (RiBi) inhibition and nucleolar stress, likely driving previously observed PT-112-induced cancer organelle stresses and ICD.